博拓生物(688767.SH):公司的甲、乙流感診斷試劑產品具有明顯的比較優勢
格隆匯12月4日丨博拓生物(688767.SH)近期在接待機構投資者調研時表示,根據近期中國國家流感中心數據,與往年對比,流感感染上升期相對提前,且為多種病原體混合感染,伴隨着新冠疫情結束後,傳播現狀相對往年更為複雜。進入冬春季後,預計後續呼吸道病原體傳播會繼續增強,誘發呼吸道相關疾病,傳播期或至明年3月,這也是每年呼吸道傳播疾病的高發期,具有較為明顯的季節性,其中又以甲流作為主要呼吸道傳染病。因此,作為國內較少具有甲、乙流檢測醫療器械證書的企業之一,公司的甲、乙流感診斷試劑產品具有明顯的比較優勢,產品也進入快速出貨期,公司將會視流感流行週期情況有序擴產以確保及時向各客户供應產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.